Dietary sodium restriction: A neglected therapeutic opportunity in chronic kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 23, Issue 6, 2014, Pages 533-540

  Humalda, Jelmer K ^a   Navis, Gerjan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Chronic kidney disease; Renin angiotensin aldosterone system blockade; Sodium restriction; Volume status

Indexed keywords

BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; EXTRACELLULAR SPACE; HUMAN; LIFESTYLE MODIFICATION; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM EXCRETION; SODIUM INTAKE; SODIUM RESTRICTION; SODIUM URINE LEVEL; URINALYSIS; ADVERSE EFFECTS; ATTITUDE TO HEALTH; DIET THERAPY; ELECTROLYTE BALANCE; HEALTH BEHAVIOR; LIFESTYLE; PATHOPHYSIOLOGY; PATIENT EDUCATION; PSYCHOLOGY; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SALT INTAKE; TREATMENT OUTCOME;

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SALT INTAKE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIET, SODIUM-RESTRICTED; HEALTH BEHAVIOR; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LIFE STYLE; PATIENT EDUCATION AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; SODIUM CHLORIDE, DIETARY; TREATMENT OUTCOME; WATER-ELECTROLYTE BALANCE;

EID: 84927174943     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000073     Document Type: Review

References (46)

1. Beaglehole R, Bonita R, Horton R, et al. Priority actions for the noncommunicable disease crisis. Lancet 2011; 377:1438-1447.
2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group.KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013; 3:1-150.
3. Bibbins-Domingo K, Chertow GM, Coxson PG, et al. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med 2010; 362:590-599.
4. Lambers Heerspink HJ, Holtkamp FA, Parving HH, et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int 2012; 82:330-337.
5. Kwakernaak AJ, Krikken JA, Binnenmars SH, et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. Lancet Diabetes Endocrinol 2014; 2:385-395.
6. Vegter S, Perna A, Postma MJ, et al. Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol 2012; 23:165-173.
7. van Zuilen AD, Bots ML, Dulger A, et al. Multifactorial intervention with nurse practitioners does not change cardiovascular outcomes in patients with chronic kidney disease. Kidney Int 2012; 82:710-717.
8. Vogt L, Waanders F, Boomsma F, et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19:999-1007.
9. McMahon EJ, Bauer JD, Hawley CM, et al. A randomized trial of dietary sodium restriction in CKD. J Am Soc Nephrol 2013; 24:2096-2103.
10. Krikken JA, Lely AT, Bakker SJ, Navis G. The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int 2007; 71:260-265.
11. Navis G, de Jong PE, Donker AJ, et al. Moderate sodium restriction in hypertensive subjects: renal effects of ACE-inhibition. Kidney Int 1987; 31:815-819.
12. Slagman MC, Waanders F, Hemmelder MH, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ 2011; 343:d4366.
13. Wapstra FH, Van Goor H, Navis G, et al. Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis. Clin Sci (Lond) 1996; 90:393-401.
14. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553.
15. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369:1892-1903.
16. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:2204-2213.
17. Wilcox CS, Mitch WE, Kelly RA, et al. Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. J Lab Clin Med 1983; 102:450-458.
18. Bellomo G. Uric acid and chronic kidney disease: a time to act? World J Nephrol 2013; 2:17-25.
19. Thomas MC, Moran J, Forsblom C, et al. The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes. Diabetes Care 2011; 34:861-866.
20. Ekinci EI, Clarke S, Thomas MC, et al. Dietary salt intake and mortality in patients with type 2 diabetes. Diabetes Care 2011; 34:703-709.
21. O'Donnell MJ, Yusuf S, Mente A, et al. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA 2011; 306:2229-2238.
22. McQuarrie EP, Traynor JP, Taylor AH, et al. Association between urinary sodium, creatinine, albumin, and long-term survival in chronic kidney disease. Hypertension 2014; 64:111-117.
23. Hamming I, Navis G, Kocks MJ, van Goor H. ACE inhibition has adverse renal effects during dietary sodium restriction in proteinuric and healthy rats. J Pathol 2006; 209:129-139.
24. Boddi M, Poggesi L, Coppo M, et al. Human vascular renin-angiotensin system and its functional changes in relation to different sodium intakes. Hypertension 1998; 31:836-842.
25. Kocks MJ, Buikema H, Gschwend S, et al. High dietary sodium blunts affects of angiotensin-converting enzyme inhibition on vascular angiotensin I-toangiotensin II conversion in rats. J Cardiovasc Pharmacol 2003; 42:601-606.
26. Kocks MJ, Lely AT, Boomsma F, et al. Sodium status and angiotensinconverting enzyme inhibition: effects on plasma angiotensin-(1-7) in healthy man. J Hypertens 2005; 23:597-602.
27. Kwakernaak AJ, Waanders F, Slagman MC, et al. Sodium restriction on top of renin-angiotensin-aldosterone system blockade increases circulating levels of N-acetyl-seryl-aspartyl-lysyl-proline in chronic kidney disease patients. J Hypertens 2013; 31:2425-2432.
28. Bellizzi V, Di Iorio BR, De Nicola L, et al. Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease. Kidney Int 2007; 71:245-251.
29. Ekinci EI, Thomas G, Thomas D, et al. Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake. Diabetes Care 2009; 32:1398-1403.
30. Slagman MC, Waanders F, Vogt L, et al. Elevated N-terminal pro-brain natriuretic peptide levels predict an enhanced antihypertensive and antiproteinuric benefit of dietary sodium restriction and diuretics, but not angiotensin receptor blockade, in proteinuric renal patients. Nephrol Dial Transplant 2012; 27:983-990.
31. Svenningsen P, Friis UG, Versland JB, et al. Mechanisms of renal NaCl retention in proteinuric disease. Acta Physiol (Oxf) 2013; 207:536-545.
32. Visser FW, Krikken JA, Muntinga JH, et al. Rise in extracellular fluid volume during high sodium depends on BMI in healthy men. Obesity (Silver Spring) 2009; 17:1684-1688.
33. Machnik A, Neuhofer W, Jantsch J, et al. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-Cdependent buffering mechanism. Nat Med 2009; 15:545-552.
34. Andrukhova O, Slavic S, Smorodchenko A, et al. FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med 2014; 6:744-759.
35. Baia LC, Humalda JK, Vervloet MG, et al. Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation. Clin J Am Soc Nephrol 2013; 8:1968-1978.
36. Zoccali C, Ruggenenti P, Perna A, et al. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol 2011; 22:1923-1930.
37. Hung SC, Kuo KL, Peng CH, et al. Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease. Kidney Int 2014; 85:703-709.
38. Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007; 334:885-888.
39. Robare JF, Bayles CM, Newman AB, et al. The '10 keys' to healthy aging: 24-month follow-up results from an innovative community-based prevention program. Health Educ Behav 2011; 38:379-388.
40. Zhang SX, Guo HW, Wan WT, Xue K. Nutrition education guided by Dietary Guidelines for Chinese Residents on metabolic syndrome characteristics, adipokines and inflammatory markers. Asia Pac J Clin Nutr 2011; 20:77-86.
41. Carrigan A, Klinger A, Choquette SS, et al. Contribution of food additives to sodium and phosphorus content of diets rich in processed foods. J Ren Nutr 2014; 24:13-19; 19e1.
42. Ix JH, Wassel CL, Stevens LA, et al. Equations to estimate creatinine excretion rate: the CKD epidemiology collaboration. Clin J Am Soc Nephrol 2011; 6:184-191.
43. Smyth A, Dunkler D, Gao P, et al. The relationship between estimated sodium and potassium excretion and subsequent renal outcomes. Kidney Int 2014; doi: 10.1038/ki.2014.214. [Epub ahead of print]
44. Joosten MM, Gansevoort RT, Mukamal KJ, et al. Urinary and plasma magnesium and risk of ischemic heart disease. Am J Clin Nutr 2013; 97:1299-1306.
45. van den Berg E, Pasch A, Westendorp WH, et al. Urinary sulfur metabolites associate with a favorable cardiovascular risk profile and survival benefit in renal transplant recipients. J Am Soc Nephrol 2014; 25:1303-1312.
46. Sinkeler SJ, Kwakernaak AJ, Bakker SJ, et al. Creatinine excretion rate and mortality in type 2 diabetes and nephropathy. Diabetes Care 2013; 36: 1489-1494.